These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 10391533)

  • 21. Advanced primary peritoneal carcinoma: clinicopathological and prognostic factor analyses.
    Zhang C; Li XP; Cui H; Shen DH; Wei LH
    J Zhejiang Univ Sci B; 2008 Jun; 9(6):435-40. PubMed ID: 18543395
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Value of topoisomerase II alpha, MIB-1, p53, E-cadherin, retinoblastoma gene protein product, and HER-2/neu immunohistochemical expression for the prediction of biologic behavior in adrenocortical neoplasms.
    Gupta D; Shidham V; Holden J; Layfield L
    Appl Immunohistochem Mol Morphol; 2001 Sep; 9(3):215-21. PubMed ID: 11556748
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immunohistochemical markers of cell cycle control applied to ovarian and primary peritoneal surface epithelial neoplasms: p21(WAF1/CIP1) predicts survival and good response to platinin-based chemotherapy.
    Costa MJ; Hansen CL; Walls JE; Scudder SA
    Hum Pathol; 1999 Jun; 30(6):640-7. PubMed ID: 10374771
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prognostic and predictive effects of immunohistochemical factors in high-risk primary breast cancer patients.
    Kröger N; Milde-Langosch K; Riethdorf S; Schmoor C; Schumacher M; Zander AR; Löning T
    Clin Cancer Res; 2006 Jan; 12(1):159-68. PubMed ID: 16397038
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Expression of p53, CD44, Ki-67, and HER-2/neu Markers in Gastric Cancer and Its Association with Histopathological Indicators: A Retrospective Study.
    Ahadi M; Moradi A; Musavinejad L; Movafagh A; Moradi A
    Asian Pac J Cancer Prev; 2020 Jun; 21(6):1607-1614. PubMed ID: 32592354
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cyclooxygenase-2 (COX-2), epidermal growth factor receptor (EGFR), and Her-2/neu expression in ovarian cancer.
    Ferrandina G; Ranelletti FO; Lauriola L; Fanfani F; Legge F; Mottolese M; Nicotra MR; Natali PG; Zakut VH; Scambia G
    Gynecol Oncol; 2002 May; 85(2):305-10. PubMed ID: 11972392
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Expression of p53 and HER2/Neu in Kenyan Women With Primary Ovarian Carcinoma.
    Mutuiri AP; Nzioka A; Busarla SV; Sayed S; Moloo Z
    Int J Gynecol Pathol; 2016 Nov; 35(6):537-543. PubMed ID: 26825003
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Overexpression of HER-2/neu in uterine serous papillary cancer.
    Santin AD; Bellone S; Gokden M; Palmieri M; Dunn D; Agha J; Roman JJ; Hutchins L; Pecorelli S; O'Brien T; Cannon MJ; Parham GP
    Clin Cancer Res; 2002 May; 8(5):1271-9. PubMed ID: 12006548
    [TBL] [Abstract][Full Text] [Related]  

  • 29. CD44s expression, in benign, borderline and malignant tumors of ovarian surface epithelium. Correlation with p53, steroid receptor status, proliferative indices (PCNA, MIB1) and survival.
    Zagorianakou N; Stefanou D; Makrydimas G; Zagorianakou P; Briasoulis E; Karavasilis B; Agnantis NJ
    Anticancer Res; 2004; 24(3a):1665-70. PubMed ID: 15274338
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The expression of immunohistochemical markers estrogen receptor, progesterone receptor, Her-2-neu, p53 and Ki-67 in epithelial ovarian tumors and its correlation with clinicopathologic variables.
    Sylvia MT; Kumar S; Dasari P
    Indian J Pathol Microbiol; 2012; 55(1):33-7. PubMed ID: 22499297
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Expression of apoptosis and proliferation markers in progression of ovarian cancer].
    Antoneeva II; Petrov SB
    Patol Fiziol Eksp Ter; 2008; (4):6-7. PubMed ID: 19198263
    [TBL] [Abstract][Full Text] [Related]  

  • 32. HER-2/neu and p53 expression versus tamoxifen resistance in estrogen receptor-positive, node-positive breast cancer.
    Berry DA; Muss HB; Thor AD; Dressler L; Liu ET; Broadwater G; Budman DR; Henderson IC; Barcos M; Hayes D; Norton L
    J Clin Oncol; 2000 Oct; 18(20):3471-9. PubMed ID: 11032587
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Expression of p53 gene product and cell proliferation marker Ki-67 in Ewing's sarcoma: correlation with clinical outcome.
    Amir G; Issakov J; Meller I; Sucher E; Peyser A; Cohen IJ; Yaniv I; Ben Arush MW; Tavori U; Kollender Y; Ron N; Peylan-Ramu N
    Hum Pathol; 2002 Feb; 33(2):170-4. PubMed ID: 11957141
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Relationship between chemotherapy with paclitaxel, cisplatin, vinorelbine and titanocene dichloride and expression of proliferation markers and tumour suppressor gene p53 in human ovarian cancer xenografts in nude mice.
    Kolberg HC; Villena-Heinsen C; Deml MM; Kraemer S; Diedrich K; Friedrich M
    Eur J Gynaecol Oncol; 2005; 26(4):398-402. PubMed ID: 16122187
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immunophenotype of ovarian cancer as predictor of clinical outcome: evaluation at primary surgery and second-look procedure.
    Goff BA; Ries JA; Els LP; Coltrera MD; Gown AM
    Gynecol Oncol; 1998 Sep; 70(3):378-85. PubMed ID: 9790791
    [TBL] [Abstract][Full Text] [Related]  

  • 36. HER-2/neu overexpression in breast cancer: an immunohistochemical study including correlations with clinicopathologic parameters, p53 oncoprotein and cathepsin-D.
    Korkolis D; Ardavanis A; Yotis J; Kyroudi A; Gorgoulis V; Kittas C
    Anticancer Res; 2001; 21(3C):2207-12. PubMed ID: 11501848
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prognostic significance of p53, nm23, PCNA and c-erbB-2 in gastric cancer.
    Lee KE; Lee HJ; Kim YH; Yu HJ; Yang HK; Kim WH; Lee KU; Choe KJ; Kim JP
    Jpn J Clin Oncol; 2003 Apr; 33(4):173-9. PubMed ID: 12810831
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Expression and mutation of p53 in tumor effusion cells of patients with ovarian carcinoma: response to cisplatin-based chemotherapy.
    Bar JK; Harłozińska A; Popiela A; Noga L
    Tumour Biol; 2001; 22(2):83-91. PubMed ID: 11125280
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Non-small cell lung carcinoma: cyclin D1, bcl-2, p53, Ki-67 and HER-2 proteins expression in resected tumors.
    Radović S; Babić M; Dorić M; Hukić A; Kuskunović S; Hadzismajlović A; Serdarević F
    Bosn J Basic Med Sci; 2007 Aug; 7(3):205-11. PubMed ID: 17848143
    [TBL] [Abstract][Full Text] [Related]  

  • 40. An immunohistochemical comparison between low-grade and high-grade ovarian serous carcinomas: significantly higher expression of p53, MIB1, BCL2, HER-2/neu, and C-KIT in high-grade neoplasms.
    O'Neill CJ; Deavers MT; Malpica A; Foster H; McCluggage WG
    Am J Surg Pathol; 2005 Aug; 29(8):1034-41. PubMed ID: 16006797
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.